CRX-100 (CRX-100) - 在研适应症：晚期恶性实体瘤，结直肠癌， …
BioEclipse Therapeutics™ initiated a Phase 1 clinical trial with CRX100, a patented, first-in-class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being …
释放肿瘤治疗的潜力：下一代溶瘤病毒疗法 - 搜狐
2019年12月23日 · 公司的主要候选产品crx-100，是一种不需要肿瘤内给药，通过静脉给药用于治疗实体瘤的联合疗法。 联合免疫疗法包括免疫细胞，保护溶瘤病毒在到达肿瘤之前不被免疫 …
CRX-100 by BioEclipse Therapeutics for Non-Small Cell Lung …
2024年12月4日 · The company’s lead product candidate, CRX-100, a combined immunotherapy designed to target and kill cancer cells throughout the body while triggering an immune …
BioEclipse Receives FDA Clearance of Investigational New Drug ...
2020年4月28日 · BioEclipse Therapeutics™ is preparing to initiate Phase I clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against …
BioEclipse Therapeutics™ | NEXT GENERATION OF …
CRX100 is a combined immunotherapy currently in Phase 1b/2a clinical trial. This technology demonstrated excellent preclinical potency against a broad range of tumor types and has been …
CRX-100 - Drug Targets, Indications, Patents - Synapse
BioEclipse Therapeutics™ initiated a Phase 1 clinical trial with CRX100, a patented, first-in-class, intravenously delivered, targeted immunotherapy against solid tumors. CRX100 is being …
CRX-100-靶点_适应症: 非小细胞肺癌-临床_专利_批准
CRX-100是由斯坦福大学研发的一种细胞疗法和溶瘤病毒，是一种细胞死亡刺激剂和细胞毒性T淋巴细胞刺激剂。 目前该药物最高研发阶段为临床一期，用于治疗非小细胞肺癌、肝细胞癌、 …
BioEclipse Receives FDA Clearance of Investigational New Drug ...
2020年4月28日 · BioEclipse Therapeutics™ is preparing to initiate Phase I clinical trials with, CRX-100, a patented, first in class, intravenously delivered, targeted immunotherapy against …
Ozmosi | CRX-100 Drug Profile
CRX-100 is being developed by BioEclipse Therapeutis for the treatment of patients with advanced solid tumors. (Sourced from:
BioEclipse Therapeutics™ | Clinical Trials Overview
2015年12月25日 · Based on preclinical animal model results, combining CIK cells and virus has the potential to become a viable treatment option. CRX100 migrates to the tumor site, targets …